Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
NCT ID: NCT01543204
Last Updated: 2017-12-29
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
64 participants
INTERVENTIONAL
2012-02-01
2015-05-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Etanercept 50 mg
Participants received etanercept 50 mg, twice weekly (BIW), subcutaneously (SC) for 12 weeks followed by 50 mg, once weekly (QW), SC for an additional 12 weeks.
Etanercept
Administered by subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etanercept
Administered by subcutaneous injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Loss of satisfactory response to adalimumab
* Currently receiving or recently discontinued treatment with adalimumab
Exclusion Criteria
* Serious medical conditions
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Birmingham, Alabama, United States
Research Site
Mobile, Alabama, United States
Research Site
Phoenix, Arizona, United States
Research Site
Bakersfield, California, United States
Research Site
Encino, California, United States
Research Site
Irvine, California, United States
Research Site
Los Angeles, California, United States
Research Site
Sacramento, California, United States
Research Site
San Francisco, California, United States
Research Site
San Ramon, California, United States
Research Site
Santa Monica, California, United States
Research Site
Denver, Colorado, United States
Research Site
Farmington, Connecticut, United States
Research Site
Jacksonville, Florida, United States
Research Site
Miami, Florida, United States
Research Site
St. Petersburg, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Macon, Georgia, United States
Research Site
Skokie, Illinois, United States
Research Site
New Albany, Indiana, United States
Research Site
Plainfield, Indiana, United States
Research Site
Louisville, Kentucky, United States
Research Site
New Orleans, Louisiana, United States
Research Site
Boston, Massachusetts, United States
Research Site
St Louis, Missouri, United States
Research Site
Omaha, Nebraska, United States
Research Site
East Windsor, New Jersey, United States
Research Site
Verona, New Jersey, United States
Research Site
Rochester, New York, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Plymouth Meeting, Pennsylvania, United States
Research Site
Johnston, Rhode Island, United States
Research Site
Charleston, South Carolina, United States
Research Site
Bartlett, Tennessee, United States
Research Site
Knoxville, Tennessee, United States
Research Site
Nashville, Tennessee, United States
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Norfolk, Virginia, United States
Research Site
Walla Walla, Washington, United States
Research Site
Winnipeg, Manitoba, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
Markham, Ontario, Canada
Research Site
Peterborough, Ontario, Canada
Research Site
Waterloo, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bagel J, Tyring S, Rice KC, Collier DH, Kricorian G, Chung J, Iles J, Stolshek BS, Kaliyaperumal A, Papp KA. Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab. Br J Dermatol. 2017 Aug;177(2):411-418. doi: 10.1111/bjd.15381. Epub 2017 Jul 19.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20101145
Identifier Type: -
Identifier Source: org_study_id